Visão geral da empresa
A development-stage pharmaceutical company, Tenax Therapeutics, Inc., focuses on creating novel cardiopulmonary therapies specifically within the United States market. The firm operates within the Healthcare sector, specifically targeting the Biotechnology industry, which implies a high-risk, high-reward profile characterized by significant capital expenditure for research and development before potential commercialization. The company's market capitalization stands at $258.82M, while its annual revenue is not disclosed, and it employs 14 individuals to execute its strategic initiatives. The combination of a market cap of $258.82M and the absence of reported annual revenue figures indicates that the company is in an early-stage operational phase where value is derived primarily from intellectual property and pipeline assets rather than current sales volume, reflecting a typical structure for biotechnology entities pursuing novel treatments for pulmonary hypertension.
Saúde financeira
Tenax Therapeutics reports no revenue and a net income of $-52,599,000 over the trailing twelve months, with EBITDA also listed as N/A, revealing a cost structure dominated by substantial R&D expenses and operational overheads that have not yet been offset by commercial sales. The company generated free cash flow of $-18,441,624, indicating a consistent cash burn rate that necessitates ongoing access to capital markets or private funding to sustain operations and advance clinical trials. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a standard characteristic for pre-revenue biotechnology firms where no sales occur to generate a margin percentage. On the balance sheet, the company holds $97.56M in cash against $0 in debt, resulting in a debt-to-equity ratio that is N/A, which signifies a highly conservative financial position free from leverage obligations. The current ratio stands at 14.56, suggesting exceptionally strong short-term liquidity and the ability to cover short-term liabilities many times over with available assets. Return on Equity is recorded at -55.6% and Return on Assets at -35.1%, metrics that reflect the dilution of shareholder value and asset efficiency due to the heavy investment in clinical development rather than profit generation typical of mature pharmaceutical companies.
Avaliação de valorização
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -10.29, implying that the market currently prices in negative earnings expectations or anticipates a significant turnaround in profitability in the near future. The price-to-book ratio is 6.58, indicating that the market values the company at a substantial premium over its book value, a common valuation multiple for biotechnology firms where intangible assets and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are both N/A, suggesting that traditional valuation frameworks are not applicable until the company generates positive revenue streams and sustainable earnings. The stock has a 52-week high of $18.38 and a 52-week low of $4.63, placing the current trading range within a wide volatility band that reflects the uncertainty surrounding the company's clinical trial outcomes and commercial prospects. With a beta of 1.19, the stock exhibits higher price volatility relative to the broader market, moving with greater intensity than the S&P 500, which is characteristic of small-cap biotechnology stocks with limited liquidity and high sensitivity to sector-specific news.
Growth & Income
Tenax Therapeutics reports no revenue growth or earnings growth rates as the metrics are N/A, meaning there is no historical data to compare current performance against, which is typical for companies in the development stage prior to market entry. Since the company does not pay dividends, there is no dividend yield or payout ratio to analyze, confirming that all available cash is being reinvested directly into the development of TNX-101, TNX-102, and TNX-103 rather than distributed to shareholders. The absence of a payout ratio is sustainable given the current net loss, as distributing dividends would be financially imprudent without positive earnings. Overall, the growth and income profile is defined entirely by the potential future value of its clinical pipeline rather than current financial performance or shareholder distributions.